Aplastic anemia,Thrombocytopenia
Conditions
Interventions
Group 1:Add rhTPO, 300U/kg qd after ATG treatment for 8 weeks
Group 2:Add rhTPO, 300U/kg qod after ATG treatment for 8 weeks
Sponsors
Institute of Hematology, People's Hospital, Peking University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Patients diagnosed with SAA who consent to ATG/CsA treatment. The diagnostic criteria refer to the 2017 Consensus on Diagnosis and Treatment of Aplastic Anemia [5]: (1) The degree of bone marrow cell proliferation is <25% of normal; if = normal 25% but <50%, the remaining hematopoietic cells should be <30%; (2) blood routine: need to have two of the following three: ANC <0.5×10^9/L; corrected reticulocyte <1% or absolute value <20 × 10^9/L; BPC <20 × 10^9/L; (3) If ANC<0.2×10^9/L is a very heavy aplastic anemia (VSAA); 2. Aged 18 to 65 years old, male or female; 3. Those who can be hospitalized for more than 2 months; 4. There is no obvious abnormality in liver and kidney function (serum urea nitrogen, creatinine, transaminase, bilirubin are = 2.5 times the upper limit of normal); 5. According to the New York Heart Association (NYHA) grading standard, cardiac dysfunction = level 2; 6. Female subjects with fertility were negative for serum pregnancy test (screening period); 7. The patient voluntarily signed a written informed consent form indicating his willingness to participate in the study.
Exclusion criteria
Exclusion criteria: 1. Congenital hematopoietic failure, fanconi anemia; 2. Cytogenetics confirmed patients with abnormal cloning; 3. The HBV DNA detection copy number is greater than 1000/mL, and the serum hepatitis B virus is not cleared; 4. With recent thrombosis or high risk of thrombosis; 5. With serious and uncontrollable infection; 6. Patients with severe heart disease, lung disease, kidney disease, liver disease; 7. Patients with other tumors at the same time; 8. Women during lactation and pregnancy; 9. The investigator believes that the patient is not eligible to participate in any other case of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 3 months detachment rate of platelet transfusion; | — |
Secondary
| Measure | Time frame |
|---|---|
| TPO concentration;Platelet count;overall response rate; | — |
Countries
China
Contacts
Public ContactJia Jinsong
Institute of Hematology, People's Hospital, Peking University
Outcome results
None listed